Characterizing Adherence to Treatment and Satisfaction With Care in Patients With Cutaneous Lupus
Cross-sectional Multicenter Study Aimed at Characterizing Adherence to Treatment and Satisfaction With Care in Patients With Cutaneous Lupus
About This Trial
This multicenter study aims to evaluate treatment adherence and satisfaction of patients with cutaneous lupus, influenced by perception of the disease, fear of side effects, cost of medications and the doctor-patient relationship. Adherence will be measured by a VAS of 80% or higher on the Medical Adherence Self-Report Inventory scale.
Who May Be Eligible (Plain English)
Original Eligibility Criteria
View original clinical language
Treatments Being Tested
Questionnaires
Responses to questionnaires: * Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) * Medical Adherence Self-Report Inventory (MASRI) * Morisky Medication Adherence Scale (MMAS4) * Visual analog scale (VAS) on the perception of disease control * Belief on Medicine Questionnaire (BMQ) * Care patient Feedback measure * Hospital Anxiety and Depression Scale (HAD) * Dermatology Life Quality Index (DLQI)